All In Biotech

Drug Trial Radar · NCT05569772

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes: a Double Blind RCT

Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 252 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

252

Planned (sponsor's estimate)

Start

Sep 14, 2023

Primary completion

Mar 2030

Study completion May 2030

Sponsor

Lead sponsor
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University Hospital, Antwerp; Universitair Ziekenhuis Brussel; General Hospital Groeninge; Vitaz; Centre Hospitalier Universitaire de Liege; Erasme University Hospital; Centre Hospitalier Mouscron; Jan Yperman Ziekenhuis; AZ Turnhout; AZ Sint-Lucas Brugge; Ziekenhuis aan de Stroom; Onze Lieve Vrouw Hospital
First posted
Oct 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Gestational diabetes (GDM) is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who will develop T2DM within 5 years after the delivery. Moreover, women with a history of GDM progress more rapidly to T2DM compared to women with similarly elevated glucose levels. Early intervention after the index pregnancy is therefore crucial to prevent T2DM. With the SERENA project, the investigators aim to reduce the risk to develop T2DM with the long-acting GLP-1 agonist semaglutide in women with a recent history of GDM and glucose intolerance in early postpartum.

Conditions

  • Glucose Intolerance After a Recent History of Gestational Diabetes

Interventions

  • Semaglutide Pen InjectorDrug

    maintenance dose of 1mg SC once weekly

  • Semaglutide placeboDrug

    maintenance dose of 1mg SC once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Development of T2DMTime frame: by 160 weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • AZORG

    Aalst, Belgium · Recruiting

  • UZA

    Antwerp, Belgium · Recruiting

  • ZAS

    Antwerp, Belgium · Recruiting

  • AZ St Jan Brugge

    Bruges, Belgium · Recruiting

  • Erasme

    Brussels, Belgium · Recruiting

  • UZ Brussel

    Brussels, Belgium · Recruiting

  • Jan Yperman

    Ieper, Belgium · Recruiting

  • AZ Groeninge Kortrijk

    Kortrijk, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • CHU de Liège

    Liège, Belgium · Recruiting

  • Centre Hospitalier Mouscron

    Mouscron, Belgium · Recruiting

  • Vitaz

    Sint-Niklaas, Belgium · Recruiting

  • AZ Turnhout

    Turnhout, Belgium · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.